Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients

Although high-dose chemotherapy is the gold standard for the treatment of many relapsed or refractory lymphomas, the outcome remains unsatisfactory, particularly in some subsets of patients with adverse prognostic features. Here we report the outcome of 111 high-risk lymphoma patients treated with a

[1]  L. Giordano,et al.  High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant , 2015, Bone Marrow Transplantation.

[2]  J. Vose,et al.  Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  J. Kurtzberg,et al.  Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma , 2014, Leukemia.

[4]  N. Schmitz,et al.  Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. , 2014, The Lancet. Oncology.

[5]  K. Ardeshna,et al.  A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma , 2013, Leukemia.

[6]  R. Bouabdallah,et al.  Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin’s lymphoma , 2013, Bone Marrow Transplantation.

[7]  G. Sauvageau,et al.  Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  N. Schmitz,et al.  Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Sandmaier,et al.  Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  J. Garcia-conde,et al.  Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term outcomes , 2007, British journal of haematology.

[11]  A. Romanelli,et al.  Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  É. Lepage,et al.  Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients , 1996, Cancer.

[13]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[14]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[15]  J. Connors,et al.  Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988. , 1991, Blood.